Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00350025 · ClinicalTrials.gov registry record · Phase 2
Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer
A Phase 2 study, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT00350025 is a Phase 2 study that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 41 participants.
The verdict
NCT00350025, a Phase 2 study, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine whether the investigational drug cetuximab, (Erbitux) alone or with paclitaxel (Taxol) can stabilize the growth of urothelial cancer.
Interventions
- DRUG Paclitaxel
- DRUG Cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2006-08 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00350025
The ClinicalTrials.gov registry entry for NCT00350025 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel is the first listed.
NCT00350025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00350025 about?
NCT00350025 is a clinical study titled "Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer". The purpose of this research study is to determine whether the investigational drug cetuximab, (Erbitux) alone or with paclitaxel (Taxol) can stabilize the growth of urothelial cancer.
What is the current status of trial NCT00350025?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2006-08. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00350025?
The interventions under investigation include: Paclitaxel (DRUG), Cetuximab (DRUG).
Who is sponsoring clinical trial NCT00350025?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.